title: Field Trial of an Aerially-Distributed Tuberculosis Vaccine in a Low-Density Wildlife Population of Brushtail Possums (Trichosurus vulpecula).
abstract: Oral-delivery Mycobacterium bovis bacillus Calmette-Guérin (BCG) vaccine in a lipid matrix has been shown to confer protection against M. bovis infection and reduce the severity of tuberculosis (TB) when fed to brushtail possums (Trichosurus vulpecula), the major wildlife vector of bovine TB in New Zealand. Here we demonstrate the feasibility of aerial delivery of this live vaccine in bait form to an M. bovis-infected wild possum population, and subsequently assess vaccine uptake and field efficacy. Pre-trial studies indicated a resident possum population at very low density (<0.6 possums/ha) at the field site, with a 5.1% prevalence of macroscopic TB lesions. Pilot studies indicated that flavoured lipid matrix baits in weather-proof sachets could be successfully sown aerially via helicopter and were palatable to, and likely to be consumed by, a majority of wild possums under free-choice conditions. Subsequently, sachet-held lipid baits containing live BCG vaccine were sown at 3 baits/ha over a 1360 ha area, equating to >5 baits available per possum. Blood sampling conducted two months later provided some evidence of vaccine uptake. A necropsy survey conducted one year later identified a lower prevalence of culture-confirmed M. bovis infection and/or gross TB lesions among adult possums in vaccinated areas (1.1% prevalence; 95% CI, 0-3.3%, n = 92) than in unvaccinated areas (5.6%; 0.7-10.5%, n = 89); P = 0.098. Although not statistically different, the 81% efficacy in protecting possums against natural infection calculated from these data is within the range of previous estimates of vaccine efficacy in trials where BCG vaccine was delivered manually. We conclude that, with further straightforward refinement to improve free-choice uptake, aerial delivery of oral BCG vaccine is likely to be effective in controlling TB in wild possums. We briefly discuss contexts in which this could potentially become an important complementary tool in achieving national eradication of TB from New Zealand wildlife.
authors.affiliation: Landcare Research - Manaaki Whenua, Lincoln, New Zealand.
authors.forename: Graham
authors.initials: G
authors.lastname: Nugent
authors.affiliation: Landcare Research - Manaaki Whenua, Lincoln, New Zealand.
authors.forename: Ivor J
authors.initials: IJ
authors.lastname: Yockney
authors.affiliation: Landcare Research - Manaaki Whenua, Lincoln, New Zealand.
authors.forename: E Jackie
authors.initials: EJ
authors.lastname: Whitford
authors.affiliation: Landcare Research - Manaaki Whenua, Lincoln, New Zealand.
authors.forename: Martin L
authors.initials: ML
authors.lastname: Cross
authors.affiliation: Centre for Innovation, University of Otago, Dunedin, New Zealand.
authors.forename: Frank E
authors.initials: FE
authors.lastname: Aldwell
authors.affiliation: AgResearch, Hopkirk Institute, Palmerston North, New Zealand.
authors.forename: Bryce M
authors.initials: BM
authors.lastname: Buddle
mesh_terms: D000388:Air; D000818:Animals; D001500:BCG Vaccine / Q000008:administration & dosage* / Q000276:immunology; D002417:Cattle; D004197:Disease Reservoirs / Q000662:veterinary*; D005260:Female; D008055:Lipids; D008297:Male; D009163:Mycobacterium bovis / Q000276:immunology*; D048330:Trichosurus / Q000382:microbiology*; D032581:Tuberculosis Vaccines / Q000008:administration & dosage* / Q000276:immunology; D014380:Tuberculosis, Bovine / Q000453:epidemiology / Q000517:prevention & control*
chemical_list: D001500:BCG Vaccine; D008055:Lipids; D032581:Tuberculosis Vaccines